Category: News
-
Endometriosis study uncovers molecular subgroups to guide trials
Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
SweetBio’s honey-based bandage saving limbs and closing wounds
The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.
-
Old becomes New: CNS Pharma’s quest to tackle brain cancers
CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.
-
Secura Bio’s Copiktra PTCL data shines at ASH 2025
The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.
-
FoRx secures $50 million to advance PARG inhibitor
Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.
-
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
-
SABCS25: Agendia’s genomic testing guides breast cancer care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
-
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson’s treatment.
-
VUGENE partners with Inotiv to power AI-driven drug discovery
Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.
-
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
-
Sanofi’s ASH 2025: Redefining rare blood disorder care
Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company’s dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.